Related Experiment Videos

[Clinical study of 28 children with bacterial meningitis]

Naoko Ogasawara1, Izumi Ichihasi, Yuichirou Tsuji

  • 1Department of Pediatrics, School of Medicine, Showa University, Tokyo, Japan.

Insights

Initial bacterial meningitis treatment in infants requires dual antibiotics, not single agents. Emerging antibiotic resistance necessitates exploring new drug combinations beyond cefotaxime and ampicillin for improved infant outcomes.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Microbiology

Background:

  • Bacterial meningitis remains a significant cause of infant morbidity and mortality.
  • Antibiotic resistance poses a growing challenge to effective treatment strategies.

Purpose of the Study:

  • To retrospectively analyze bacterial meningitis cases in infants treated between 1988 and 2002.
  • To evaluate the effectiveness of initial antibiotic regimens and identify factors influencing prognosis.
  • To recommend updated treatment guidelines based on observed resistance patterns.

Main Methods:

  • Retrospective chart review of 28 pediatric patients diagnosed with bacterial meningitis.
  • Identification of causative pathogens and analysis of antibiotic susceptibility.
  • Evaluation of treatment regimens, including cefotaxime (CTX) and ampicillin (ABPC) combinations.
  • Assessment of clinical outcomes, sequelae, and mortality in relation to diagnostic factors.

Main Results:

  • Haemophilus influenzae was the predominant pathogen in infants over 1 month (72.2%).
  • Cefotaxime and ampicillin combination was the most frequent initial treatment (67.9%).
  • One case exhibited resistance to both cefotaxime and ampicillin, highlighting emerging resistance.
  • Infants under 1 year old were exclusively affected in cases with sequelae or mortality.
  • Hospital admission delay and convulsions did not correlate with prognosis.

Conclusions:

  • Current treatment for infant bacterial meningitis should involve dual antibiotic therapy.
  • Conventional cefotaxime and ampicillin combinations may be insufficient due to resistance.
  • Development and consideration of novel antibiotic combinations are crucial for improved treatment efficacy.

Related Concept Videos

Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
Bacterial Meningitis01:24

Bacterial Meningitis

Bacterial meningitis is a severe infectious disease involving inflammation of the meninges, the protective membranes surrounding the brain and spinal cord. It occurs when pathogenic bacteria cross the blood–brain barrier and enter the cerebrospinal fluid. Common causative organisms include Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b, Listeria monocytogenes, and Escherichia coli K1. The exact route of entry varies by pathogen and host condition.Routes of Entry...
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...